<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">0370121</journal-id>
<journal-id journal-id-type="pubmed-jr-id">6712</journal-id>
<journal-id journal-id-type="nlm-ta">Prog Neurobiol</journal-id>
<journal-id journal-id-type="iso-abbrev">Prog. Neurobiol.</journal-id>
<journal-title-group>
<journal-title>Progress in neurobiology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0301-0082</issn>
<issn pub-type="epub">1873-5118</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">26721620</article-id>
<article-id pub-id-type="pmc">5114175</article-id>
<article-id pub-id-type="doi">10.1016/j.pneurobio.2015.12.002</article-id>
<article-id pub-id-type="manuscript">NIHMS757198</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Challenges in the development of therapeutics for narcolepsy</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Black</surname>
<given-names>Sarah Wurts</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yamanaka</surname>
<given-names>Akihiro</given-names>
</name>
<xref ref-type="aff" rid="A2">b</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kilduff</surname>
<given-names>Thomas S.</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>a</label> Center for Neuroscience, Biosciences Division, SRI International, Menlo Park, CA 94025, USA</aff>
<aff id="A2"><label>b</label> Research Institute of Environmental Medicine, Nagoya University, Nagoya 464-8601, Japan</aff>
<author-notes>
<corresp id="CR1"><label>*</label> Corresponding author at: Center for Neuroscience, Biosciences Division, SRI International, 333 Ravenswood Avenue, Menlo Park, CA 94025, USA. Tel.: +1 650 859 5509. <email>thomas.kilduff@sri.com</email> (T.S. Kilduff).</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>3</day>
<month>11</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>23</day>
<month>12</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="ppub">
<month>5</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>5</month>
<year>2018</year>
</pub-date>
<volume>152</volume>
<fpage>89</fpage>
<lpage>113</lpage>
<!--elocation-id from pubmed: 10.1016/j.pneurobio.2015.12.002-->
<abstract>
<p id="P1">Narcolepsy is a neurological disorder that afflicts 1 in 2000 individuals and is characterized by excessive daytime sleepiness and cataplexyâ€”a sudden loss of muscle tone triggered by positive emotions. Features of narcolepsy include dysregulation of arousal state boundaries as well as autonomic and metabolic disturbances. Disruption of neurotransmission through the hypocretin/orexin (Hcrt) system, usually by degeneration of the HCRT-producing neurons in the posterior hypothalamus, results in narcolepsy. The cause of Hcrt neurodegeneration is unknown but thought to be related to autoimmune processes. Current treatments for narcolepsy are symptomatic, including wake-promoting therapeutics that increase presynaptic dopamine release and anticataplectic agents that activate monoaminergic neurotransmission. Sodium oxybate is the only medication approved by the US Food and Drug Administration that alleviates both sleep/wake disturbances and cataplexy. Development of therapeutics for narcolepsy has been challenged by historical misunderstanding of the disease, its many disparate symptoms and, until recently, its unknown etiology. Animal models have been essential to elucidating the neuropathology underlying narcolepsy. These models have also aided understanding the neurobiology of the Hcrt system, mechanisms of cataplexy, and the pharmacology of narcolepsy medications. Transgenic rodent models will be critical in the development of novel therapeutics for the treatment of narcolepsy, particularly efforts directed to overcome challenges in the development of hypocretin replacement therapy.</p>
</abstract>
<kwd-group>
<kwd>Narcolepsy</kwd>
<kwd>Cataplexy</kwd>
<kwd>Orexin</kwd>
<kwd>Hypocretin</kwd>
<kwd>Neurodegeneration</kwd>
<kwd>Animal models</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>